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Abstract Tissue based research requires a background in
human and veterinary pathology, developmental biology,
anatomy, as well as molecular and cellular biology. This
type of comparative tissue biology (CTB) expertise is nec-
essary to tackle some of the conceptual challenges in hu-
man breast stem cell research. It is our opinion that the
scarcity of CTB expertise contributed to some erroneous
interpretations in tissue based research, some of which are
reviewed here in the context of breast stem cells. In this
article we examine the dissimilarities between mouse and
human mammary tissue and suggest how these may im-
pact stem cell studies. In addition, we consider the differ-
ences between breast ducts vs. lobules and clarify how
these affect the interpretation of results in stem cell re-
search. Lastly, we introduce a new elaboration of normal
epithelial cell types in human breast and discuss how this
provides a clinically useful basis for breast cancer
classification.
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Abbreviations
CTB Comparative tissue biology
TDLU Terminal ductal lobular unit
TEB Terminal end bud
CD Cluster differentiation
FACS Fluorescent activated cell sorting
IHC Immunohistochemistry
TNBC Triple negative breast carcinoma




VDR Vitamin D receptor
K5 Keratin 5
LCIS Lobular carcinoma in situ
DCIS Ductal carcinoma in situ
Introduction
Integration of experimental results from multiple species
and correlating these with human disease pathology is a
multidisciplinary challenge [1]. In the case of normal
breast stem cell research, this challenge includes corre-
lating results obtained in mouse models with human
tissues [2]. Furthermore, the insights gleaned from
studying normal cellular lineages must be related to dis-
ease states [3, 4]. This integration process has not been
always successful, partly due to lack of communication
between different fields of research, decreasing number
and lack of involvement of CTB experts [1, 5–8]. Here,
we examine some of the factors that contribute to these
challenges.
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Human versus Mouse Models in Mammary Stem Cell
Biology
Several rigorous experiments demonstrated that a single nor-
mal mouse mammary stem cell can re-generate an entire glan-
dular tree capable of producing milk in five serial transplan-
tations [9]. Such an experiment fulfills the most stringent
in vivo test for the identification of oligopotential stem cells
in the mouse mammary gland.
For obvious reasons related to size, an entire human mam-
mary gland or even an entire mammary lobe cannot be gener-
ated in the mouse mammary fat pad. In xenotransplantation
experiments, human cells generate at best the equivalent of a
very small mammary terminal duct unit, but no primary or
secondary ducts, and they do not repopulate the entire fat-
pad. So far, successful xenotransplantation cannot be achieved
from single human mammary cells.
To date, the lowest number of human mammary epithelial
cells implanted in the humanized clear fat pad of immunodefi-
cient mice that generated outgrowths was ten cells, representing
the mammosphere initiating cells [10]. In the same study by
Pece et al., the lowest number of cells prospectively isolated
from normal breast tissue which generated outgrowths when
implanted in vivo was 500 cells. These represented the in vivo
equivalent of mammosphere initiating cells [10].
One should note, however, that the in vivo outgrowths of
human cells only form ducts right around the implantation site
and do not form a complete ductular tree across the fat-pad
like the mouse cells. What are the reasons for the failure of a
single human cell to repopulate the entire mouse mammary
fat-pad? One answer might be that there are no oligopotential
stem cells in the adult human breast. Alternatively, it is possi-
ble that the correct oligopotential cell subpopulation has not
been isolated so far. A third possibility is that cross-species
differences between human and mice may not permit such an
experiment to succeed. In this section we will consider the
latter two possibilities with a particular attention to compara-
tive tissue biology and hormonal states.
& There are significant differences between the architecture
of rodent versus human breast.
1. The mouse mammary gland is a network of ducts
ending in stem-cell enriched structures called terminal
end buds (TEBs), which drive further duct elongation
and branching in subsequent developmental stages.
In contrast, the human mammary gland has a more
complex structure, consisting of 17–30 individual
lobes, each of them connected to the nipple. Lobules
emerge through side-branching from the big ducts, to
which they are connected through secondary ducts.
Lobules have been classified in three types depending
on maturity and branching complexity plus an
additional fourth type, seen only in the lactating mam-
mary gland, which contains alveoli filled with milk
[11, 12]. The development of the human mammary
gland is not synchronous. Lobules of all three types
can be seen in adjacent positions in relation to the
primary ducts. Entire lobes may be excluded from lac-
tation, having only undeveloped lobules. The function-
al unit of the mammary gland is a collection of duct-
ules in the composition of the lobules, the terminal
ductal lobular unit (TDLU). Although it has been pro-
posed to be the functional equivalent of the TEB in the
mouse mammary gland, it has a different structure and
it is not clear if it is enriched in stem or progenitor cells.
2. The intra-lobular stroma of the human breast lobule,
referred to as ‘specialized stroma’, is absent in mice.
This stroma is cellular and it is typified by ‘loose’ col-
lagen mixed with hyaluronin and other matrix proteins
that envelope human TDLU. The entire TDLU struc-
ture is surrounded by dense extra-lobular stroma that is
not as cellular as the intra-lobular stroma; it is predomi-
nantly composed of dense collagen that forms a thick
layer between the TDLU and surrounding adipose
tissue (Fig. 1a). In contrast, mouse mammary gland is
mostly composed of adipose tissue that directly juxta-














Fig. 1 Differences in the microanatomy of human vs. mouse breast. a
Normal human breast section. The solid pink background highlights the
dense stroma with mature collagen surrounding ducts and lobules
(Hematoxylin-eosin (H&E) stain of formalin-fixed paraffin-embedded
(FFPE), 40×). b Normal mouse breast lacks the dense stromal
background. Most of the tissue is composed of adipose cells (H&E
stain of FFPE, 40×). c The arrow points to the interface between the
outer dense collagenous inter-lobular stroma and the inner intra-lobular
specialized stroma in human breast (H&E stain of FFPE, 400×). d
Normal mouse breast ducts are directly surrounded by the adipose
tissue, without a stromal interface. Also note that there is not a well-
formed lobular structure with branching TDLU as seen in the human
lobule in panel C (H&E stain of FFPE, 400×)
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3. There is extensive baseline branching in the resting
TDLU of human breast (Fig. 1c) [13]. In contrast,
baseline mouse mammary tree is predominantly un-
branched (Fig. 1d) [14].
4. After cessation of lactation the TEB of the mouse
mammary gland reverts back to a baseline morphol-
ogy with few branches. In contrast, human breast
TDLU remains extensively branched after lactation.
The impressive level of involution seen in mouse
breast after pregnancy and lactation is not observed
in human breast to the same extent [14].
& There are significant differences between rodent and hu-
man hormonal milieu.
1. The baseline systemic plasma estrogen hormone
levels are up to ten-fold lower in rodent compared
to primates [15].
2. Ovulation is accompanied by a significant hormonal
spike in primates that is not seen in rodents [15–17].
3. The mouse mammary fat pad is predominantly
composed of adipose cells with a scarce component
of fibroblasts (Fig. 1d) [14]. In contrast, the special-
ized stroma of human breast immediately surround-
ing the TDLU contains abundant fibroblasts with dis-
tinct surface antigens, and secrete enzymes and cyto-
kines that have a morphogenetic role in different de-
velopment stages of the breast. [18, 19] The compa-
rative representation of these specialized fibroblasts
with paracrine effects in the human breast stroma is
significantly higher than the mouse mammary
stroma. (Fig. 1c) [14].
4. Some of the species-specific mouse cytokines may
not interact with human receptors.
5. As described above, the human breast is very hetero-
geneous. In contrast, mouse mammary gland matura-
tion is generally muchmore uniform and synchronized.
& There are significant differences between rodent and hu-
man reproductive cycles.
Due to the litter size and gestational cycle differences,
there is a much greater demand on the mouse mammary
gland to produce milk compared to the human mammary
gland. Mice have an 18–20 days gestation cycle and an
average litter of 10–12 offspring. Each pup weighs 0.5–
1.5 g at birth and reaches 10–12 g by the time it is weaned,
around 3 weeks of age. The gestation cycle resumes 2–
5 days after weaning. If we extrapolated this to human
physiology, it would equal nursing ten babies that reach
half the body weight of their mother in less than a month
and potentially repeating this cycle every 2months. There-
fore, mouse mammary stem cells may be more robust and
may have a higher regenerative capacity compared to their
human counterparts.
The differences between rodents and human listed above
suggest that expecting a single human mammary stem cell to
re-populate the entire mouse mammary fat-pad may not be
realistic. The failure to do so may not be evidence against
presence of oligopotential human breast stem cells. However,
it is also worth remembering that bona fide human stem cells -
hES or iPS - can form all three germ layers in teratoma-like
structures in mice [20]. Intriguingly, cells from normal human
breast with hES like multipotential differentiation capacity
have been isolated and these cells are capable of forming
mammary outgrowths capable of lactation upon xeno-
transplantation [21]. In conclusion, given all these cross-
species differences we should not take absence of evidence
for evidence of absence regarding the existence of oligo-
potential adult human breast stem cells capable of forming
an entire gland.
Heterogeneity of Normal Human Breast Samples
Another variable one should be mindful about is the source of
the ‘normal’ breast tissue used for research. The vast majority
of normal breast tissue for research comes from cosmetic
mammary reduction surgeries. This is a self-selected patient
subpopulation that is not representative of the larger popula-
tion. Typically, patients of younger age are under-represented
and overweight patients are over-represented and Asian pa-
tients have no representation. The second source is the ‘nor-
mal’ tissue adjacent to a tumor or from the contralateral tumor-
free breast. A third source of tissue are prophylactic surgeries
in BRCAmutation carrier patients or patients with DCIS. The
concern for the two latter categories is that such tissue may be
‘tumor-free’ but not ‘normal’.
The profile of the normal cells in breast tissues originating
from cosmetic, prophylactic and therapeutic surgeries may not
be identical. The breast anatomy dictates that superficial regions
close to the nipple will have larger ducts and fewer lobules. In
contrast, tissue from deeper regions will have fewer ducts and
more lobules. It is worth pointing out that the entire mammary
gland is removed in prophylactic surgeries (BRCA), whereas
reduction mammoplasties are generally subtotal. It is not diffi-
cult to envision that sampling bias such as deep vs. superficial
tissue or concurrent contralateral tumor may play a significant
role in the apparent discordant results between different labora-
tories. In addition, age and pregnancy have been shown to
induce changes in theDNA-methylation ofmammary epithelial
cells and affect their phenotype and functionality [22]. Unfor-
tunately, in many cases these characteristics, as well as men-
strual cycle, menopausal, reproductive and previous chemo or
radiation treatment history are poorly reported in normal breast
stem cell studies. To address some of these problems normal
human breast tissue can be obtained from Komen Tissue Bank,
a collection with less population bias and uniform, standardized
methods of tissue procurement and processing.
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FACS versus In situ Identification of Rare Cells
FACS isolation of cells using cluster differentiation (CD)
markers has been the gold standard for stem cell research in
the hematopoietic field. More recently, this approach has been
used to isolate stem-enriched cell populations from solid tis-
sues, sometimes without adequate caution. Since FACS re-
quires single cell suspension as starting material, examination
of solid tissues with FACS requires mechanical dissociation
and then enzymatic digestion of the tissue, for as long as 8–
15 h. at 37 °C. During this process, the proteolytic enzymes
used to digest the tissue to single cells, as well as those that are
liberated from the tissue, are liable to cleave off antigens,
including the very stem cell markers used for FACS-enrich-
ment. Therefore, this treatment can potentially create pseudo-
marker-low subpopulations.
Once a single cell suspension is generated, the cells are
incubated with primary and secondary antibodies (1–2 h. at
4 °C) and passed through the FACS instrument (1–4 h. at
20 °C). This process has the potential to cause changes in
marker expression, antigenicity, posttranslational modifica-
tions and alterations in cellular and functional phenotype.
Furthermore, digestion of the tissue removes all the archi-
tectural and positional information, which is another draw-
back associated with using FACS in solid tissues research.
One consequence of this is the inability to know whether
two different cell populations are intermixed together or seg-
regated into different tissue zones. In particular, the destruc-
tion of the stem cell niche may impact on the ability of these
cells to grow in vivo.
For these reasons, FACS should not be used as the standalone
gold standard in solid tissue stem cell research without in situ
corroboration, which can be done with immunostaining. How-
ever, it is important to point out that unlike FACS that produces
quantitative data over a wide dynamic range, most standard im-
munostaining methods have a narrow linear range and are diffi-
cult to quantify. Emerging technology that allows for multiple
fluorochrome microscopic analysis and computer-assisted quan-
titative cell analysis may address some of these concerns [23].
However, no single approach is ideal. Therefore, relying on a
single technique and neglecting the necessity of corroborating
the same results with multiple approaches has led to several
important misconceptions in breast biology, as described below.
Location, Location, Location
Tissue stem cells are generally located in a specific and highly
restricted anatomical region. For example, the rapid-cycling
Lgr5(+) progenitor cells in the intestinal tract are restricted to
the crypt base [24]. In contrast, the slow-cycling label-retaining
Bmi1(+) stem cells are located at the +4 crypt position [25, 26].
The expression of LGR5/Bmi1 is restricted to stem/progenitor
cells and would be best described as all-or-none or bimodal,
meaning that the differentiated cells are negative for both
markers. Likewise, the CD34/K15(+) hair follicle stem cells
reside in the bulge region [27]. The expression of CD34/K15
is also bimodal; only expressed in the bulge, but not in the
isthmus or infundibular region [28]. In both tissues, this stem-
restricted bimodal pattern is accompanied by a gradient or sto-
chastic expression pattern of differentiation markers.
The in situ expression pattern of the putative FACS-based
breast stem cell markers in normal human breast tissues does
not match this well-established bimodal pattern. First, the ma-
jority of putative breast stem cell markers including CD24,
CD44, CD49, CD133, CD326, EpCAM and CD10 are
expressed throughout the breast, both in ducts and lobules.
Second, they exhibit a gradient type expression pattern
(Fig. 2a and b). Third, the cells identified by these markers
alone or in complex combinations are generally not particu-
larly rare cells. Many of the putative breast stem cell markers
are expressed in most epithelial cells, albeit at different levels
(Fig. 2a and b). These features are very unusual for a genuine
stem cell phenotype; at least they would be unusual in any
other tissue. Hence, we have to consider two possibilities:
either breast epithelium is unique and disobeys the established
patterns of tissue differentiation, or these CD markers are not
genuine stem cell markers. Between these two possibilities the
former is an exceptionalist explanation, which would require
exceptional evidence that is lacking so far.
Interestingly, there are some markers that have a bimodal
expression in normal breast epithelium such as K5, CD73 and
ALDH1A1 (Fig. 2c). However, only ALDH1A1 and CD73















Fig. 2 Differences in the expression pattern of various putative stem cell
markers. a Immunostain of normal human breast section with gradient
type CD44 expression (FFPE, 400×). b Immunostain of normal human
breast section with gradient type CD326 expression (FFPE, 400×). c
Double-immunostain of normal human breast section with bimodal
keratin 5 (brown) and CD10 (red) expression (FFPE, 100×). d Double-
immunostain of normal human breast section with bimodal ALDH1A1
(brown) and keratin 5 (red) expression (FFPE, 100×)
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broadly expressed (Fig. 2c) [29]. Intriguingly, CD73 was used
to identify multi-potent stem cells with the capacity to differ-
entiate into all three germ layers [21].
Several studies examined the potential location of the stem
cells in the ductulo-lobular tree. In one study this was done by
grossly dissecting ducts and lobules, and the results suggested
that the stem cells are located at the junction of ducts and
lobules [30]. Another study using theoretical modelling ap-
proach, concluded that the stem cells are located at end of
ductules, which represent future branching points [31]. Inter-
estingly these studies were in agreement regarding the
markers that define the mammary stem cell phenotype. It
was also suggested that there may be different stem cells for
duct vs. lobules [30]. However, these studies have been few
and far in between and more work is needed to locate the
breast stem cell compartments in situ.
Complete Description of Differentiated Cell Lineages:
A Prerequisite to Define Stem Cells
Howmany subtypes of human breast cells are there? A thought
experiment may help demonstrate the importance of this ques-
tion for stem cell research. Let us imagine that all we knew
about the cellular components of blood were presence of red
and white cells. Would we be able to decipher the differentia-
tion hierarchy of the hematopoietic cells based on this informa-
tion? Thankfully, all of the differentiated cell types including B-
lymphocytes, plasma cells, T-lymphocytes, neutrophils, eosin-
ophils, basophils, mast cells, monocytes, macrophages, mega-
karyocytes and erythrocytes were previously described. This
knowledge was essential in assessing the differentiation ability
of each putative precursor cell in the hematopoietic system.
The above thought experiment should illustrate that a com-
plete description of the differentiated cell types is a prerequi-
site to correctly describe differentiation lineages and putative
stem cells. Yet, until recently the most rigorous functional
lineage differentiation assay in breast stem cell research was
the ability of a cell to give rise to luminal or myoepithelial
cells, or both. This luminal vs. basal dichotomy must be re-
placed with a more granular description of human breast epi-
thelial cell lineages, in order to develop a detailed differentia-
tion hierarchy of human breast epithelium [23].
The new developments in multiplex immunostaining
methods has finally allowed a more detailed description of
human breast cells. In a recent study, we described eleven sub-
types of normal luminal cellular states through examining four-
teen markers simultaneously in nearly 15,000 normal breast
cells [23, 32, 33]. In a follow-up study it was found that these
cell lineages have distinct DNA methylation phenotypes, pro-
viding further evidence that they may represent different differ-
entiation states [34]. These cell subtypes are characterized by
co-expression of receptors for estrogen (ER), androgen (AR)
and vitamin-D (VDR) and keratin 5 and grouped into four
hormonal states as triple hormone receptor positive HR3
(ER+/AR+/VDR+); double hormone receptor positive HR2
(ER+/AR+, ER+/VDR+, or AR+/VDR+); single hormone re-
ceptor positiveHR1 (ER+, AR+ or VDR+) and triple hormone
receptor negative HR0 (ER-/AR-/VDR-) [28, 29].
Through these recent studies it was found that only the cells
that are negative for ER, AR, VDR and K5 are mitotically
active, suggesting that the transit amplifying progenitors in
human breast are ER (−), AR (−), VDR (−) and K5 (−) [23].
Based on this observation it was possible to imagine a putative
differentiation scheme for these normal breast cell types using
cladistic rules: that only one marker can be gained or lost at
each differentiation step and there can be a maximum of two
branches in a single step (Fig. 3a) [33]. However, alternative
models of differentiation steps are possible including a phylo-
genetic approach permitting more than two branch points aris-
ing at each step and allowing convergence into the same phe-
notype from multiple branches (Fig. 3b).
An important criterion in the selection of the fourteen line-
age markers was bimodal expression pattern associated with
clear positive and negative cell populations in situ (Fig. 4)
[23]. One insight from this study was the impressive heteroge-
neity of cellular differentiation states in the human breast
(Fig. 4) [34]. It is clear that the currently available FACS-
based putative stem cell markers that have a gradient type ex-
pression in situ (Fig. 2) would be difficult to use for isolating
cell subtypes with a bimodal in situ distribution (Fig. 4). Thus,
discovery of new stem cell markers with a bimodal in situ
distribution is needed in order to correlate stem cell populations
with hormonal states. Whether these thirteen cell types repre-
sent intermediate differentiation steps within a lineage or define
distinct lineages remains to be seen. Other important cell types
may yet have to be discovered. However, it is well known that
the ligands for ER, AR and VDR are powerful regulators of
differentiation and play a critical role in the development of
breast tissue. Thus, as opposed to the CDmarker based cellular
classification, a hormone receptor based differentiation hierar-
chy might allow us to connect the local, systemic and environ-
mental hormonal cues with cellular lineages and stem cell
differentiation.
What’s in a Name?
Some erroneous assumptions are difficult to correct despite
repeatedly being shown to be inaccurate. One example of such
a persistent misconception is the belief that breast ductal and
lobular carcinomas initiate in the ducts and lobules respectively.
Cheatle et al., discussed ductal carcinomas of the breast as
early as 1906 [35–37]. In an article published in 1941 Foote and
Stewart defined a new entity, which they named lobular carci-
noma in situ (LCIS) [38]. They described LCIS as a Bcancer
originating in lobules^ as opposed to comedo-carcinoma,
which they defined as a Bdisease of the larger duct system^
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[38]. Two decades later, in 1962, Johnson et al., referred to
‘noninfiltrative comedo-carcinoma’ as ductal carcinoma in situ
(DCIS) and wrote Bit is generally conceded that carcinoma of
the breast takes origin from either ducts or lobules^ [39].
Today, surgical pathologists are taught that Foote et al.,
were incorrect. This is based on a series of seminal articles
written by Wellings and Jensen et al., in the early 1970s [14,
40–44]. They demonstrated, through exhaustive and compre-
hensive study of entire whole-mounts of breasts from nearly
200 patients, that nearly all human breast cancers initiate in the
lobules, with the exception of rare papillomas [40, 42–45].
Their work showed that all of the precursor lesions such as
usual hyperplasia, atypical hyperplasia, ductal and lobular car-
cinoma in situ are almost exclusively seen in the lobules first
and not in ducts. This observation has been confirmed many
times by other investigators [32].
Unfortunately, the important work of Wellings et al., has
been largely ignored outside pathology. Hence, the assump-
tion of ductal origin of breast cancer persists among a consid-
erable number of basic researchers, with unintended but im-
portant consequences described below.
Luminal vs. Basal Carcinoma
Sometimes the distinctions discussed here are dismissed as
semantic, unjustifiably so when they result in misdirection
of research efforts, including a search for the origin of breast
cancer in the ducts. Furthermore, the mistaken notion of a
ductal origin of human breast cancer appears to have fed into
new misconceptions. In 1988 Dairkee et al., described a sub-
group of triple negative breast carcinomas (TNBC) that ex-
press K14 [46] and had a poor prognosis [47]. They proposed


































Fig. 3 Putative differentiation
steps in the luminal lineage of
normal human breast epithelium.
a The cladistic differentiation
model in which only one marker
can be gained or lost at each step.
In addition, no more than two
branches are allowed in a single
step. The vast majority of the cells
that are mitotically active (Mib1+/
Ki67+) in normal human breast
are K8/18+ cells that are negative
for AR/ER/VDR/K5/K14/K17/
SMA/CD10, which makes them
the only candidate for transit-
amplifying cells. b The
phylogenetic differentiation
model in which more than two
branch points are allowed at each
step. In addition, convergence
into the same phenotype from
multiple branches is permitted.
Whether these differentiation
steps are unidirectional (solid
arrows) or bidirectional (dashed
arrows) is not known at the
moment. HR0 (black), HR1
(green), HR2 (blue), HR3 (red),
















Fig. 4 Heterogeneity of cell types in human breast. a Double
immunostaining of normal human breast section with keratin 5 (red)
and smooth muscle actin (SMA, green, FFPE, 400×). b Triple
immunostaining of normal human breast section with keratin 5 (blue),
estrogen receptor (red), and androgen receptor (green). The cells that co-
express ER and AR are yellow (FFPE, 400×). c Triple immunostaining of
normal human breast section with keratin 5 (red), keratin 18 (green) and
CD10 (white). The cells that co-express K5 and K18 are yellow (FFPE,
400×). d Double-immunostaining of normal human breast section with
AR (green) and vitamin-D receptor (red). The cells that co-express AR
and VDR are yellow (FFPE, 400×)
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cells^ and added Bit is possible, therefore, that they represent
tumors of the undifferentiated basal stem cell. Interestingly,
clinical follow-up of these patients suggests that these are a
more aggressive group of tumors^ [46, 47]. However, others
found no prognostic difference among breast cancer patients
based on K5/6 and K17 expression [48].
During the early 2000s, a subset of TNBCs were found to
have high levels of K5/14/17 mRNA expression in gene ex-
pression arrays. Because of the earlier work by Dairkee et al.,
erroneously suggesting that keratins 5, 14 and 17 are exclu-
sively found in the normal myoepithelial/basal layer of ducts
in the normal breast, these tumors were eventually referred to
as basal-like carcinomas [49–52]. This appears to have led to
the misconception that while ER+ and HER2+ breast cancers
initiate in the luminal layer, the TNBC basal-like subtype
originates in the basal layer of the breast.
However, even before the use of basal-like carcinoma ter-
minology became widespread [53], several investigators had
shown that K5/14/17 can be expressed in the luminal layer of
human breast, which was largely overlooked [54–59]. More
recently, we carried out a multiplex IHC analysis of nearly 15,
000 normal breast cells [23]. This study confirmed the earlier
observations; it was found that K5/14/17 are predominantly
expressed in the luminal layer in the lobules of normal human
breast (Fig. 5) [23, 33]. Interestingly, the predominantly
myoepithelial K5/14/17 expression in the large ducts gradual-
ly switches to a predominantly luminal expression in the hu-
man breast lobules (Fig. 5) [23, 33, 60]. Thus, K5/14/17 can
be luminal or basal depending on the location of the cells in
the human mammary ductular tree. Hence, these keratins are
informative about human breast cell lineages only when the
co-expression of exclusively luminal vs. basal markers are
also known. In the original Dairkee et al., article the mouse
monoclonal antibody 312C8-1 they used was defined as
Bdirected towards human keratin 14^ and Breacts with basal
or myoepithelial cells in the human mammary .^ Significantly,
the figures that support this claim only show large ducts and
not lobules, which may explain their conclusion [46].
Several exclusively luminal markers have been identified in
the human breast including estrogen receptor (ER), androgen
receptor (AR), vitamin-D receptor (VDR), claudin-4 (Cld4) and
pan-luminal keratins K7/8/18 [23, 33]. Other markers are ex-
clusively expressed in the myoepithelial layer including
smooth-muscle actin (SMA), p63 and CD10 [23, 33]. Multi-
plex staining studies showed that luminal K5 (+) cells co-
express Cld4/K18 and they are negative for SMA/CD10
(Figs. 2, 3, 4, 5 and 6). Therefore, this expression pattern defini-
tively confirms their luminal phenotype (Figs. 2, 3, 4, 5 and 6).
In order to determine the cell-of-origin phenotype of breast
cancers, we examined the co-expression of the 14 lineage
markers in nearly two thousand human breast invasive ductal
carcinoma (IDC) samples and found that 95 % of invasive
ductal carcinomas have a pure luminal phenotype including
ER+, HER2+ and TNBCs [23, 33].
Based on this work, the triple negative cancers can be divi-
ded into three subgroups based on normal lineages; approxi-
mately one third of TNBCs are K7/8/18(+) and K5/14/
17(−) with a straight-forward luminal phenotype [23, 33]. The






B K5 CD10 K14 CD10C
luminal K14+
basal K14+luminal K5+ luminal K5-
Basal to luminal switch of K5 and K14 
Fig. 5 Differences in marker expression between breast ducts and
lobules. a Immunostaining of normal human breast section with keratin
5 (brown). The myoepithelial cells are predominantly K5(+) in the duct.
Most myoepithelial cells are K5(-) in the lobule (FFPE, 100×). b Double
immunostaining of normal human breast section with keratin 5 (brown)
and myoepithelial specific marker CD10 (red). (FFPE, 400×). c Double
immunostaining of normal human breast section with keratin 14 (brown)







Fig. 6 Example of a lobule entirely composed of luminal K5/Cld4 (+)
cells. a Immunostain of normal human breast section with keratin 5 (K5,
red, FFPE, 400×). b Immunostain of normal human breast section with
luminal specific marker claudin4 (Cld1, green, FFPE, 400×). c
Immunostain of normal human breast section with myoepithelial
specific marker SMA (green, FFPE, 400×). d Double-immunostain of
normal human breast section K5 (red) and Cld4 (green). The cells that
co-express K5 and Cld4 are yellow (FFPE, 400×)
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that has been labeled as basal-like. However, it was found that
half of these K5 (+) tumors are also VDR+/K7+/K8+/K18+
and SMA-/CD10-, as are K5 (+) normal luminal cells. There-
fore the phenotype of these tumors is better described as lumi-
nal [23]. The remaining K5(+) TNBCs expresses both luminal
(AR/VDR/K7/K8/K18) and myoepithelial (SMA/CD10)
markers. Therefore, they are best described as ‘mixed’,
luminal/myoepithelial tumors. Hence, none of the ~2,000 hu-
man breast IDCs we examined had a pure-basal like phenotype
using the normal cell lineages as a benchmark [23, 33].
It is important to emphasize that we are not arguing whether
basal-like carcinoma is a distinct molecular entity. There is
evidence that basal-like carcinomas are molecularly different
from other breast cancers [59, 61]. However; how basal-like
carcinoma is defined varies greatly among different groups [49,
55, 62, 63]. Some of the confusion is caused by the well-
documented discordance between mRNA vs. protein levels; it
was found that approximately half of the cases that are K5/6
IHC positive are mRNA negative [64]. Thus, based on IHC
they would be considered basal-like TNBC, but according to
mRNA expression they would be considered luminal-like
TNBC [64]. In addition, in the same study 14 % of K5/6 im-
munostain (IHC) negative breast cancers were found to have
high K5/6 mRNA levels [64]. Thus, in more than half of the
TNBCs there is discordance between what is considered basal-
like depending on whether mRNA or protein based markers are
used [49, 55, 59, 62, 65]. In addition, there is evidence suggest-
ing that basal-like tumors may constitute a heterogeneous um-
brella category [49, 66], harboring at least six different molec-
ular subgroups [67–71] and five different histologic subgroups
[3, 49, 55, 62, 72–75]. Nevertheless, from the perspective of
cellular lineages in the normal lobule, 95 % of invasive ductal
breast cancers undisputedly have a pure-luminal phenotype
[23]. The remaining 5 % have a mixed luminal/basal pheno-
type, and none have a pure-basal phenotype. Approximately
two thirds of TNBCs have a luminal phenotype and the remain-
ing one third has a mixed phenotype [23, 33, 53].
Interestingly, the experimental mouse models as well as
indirect evidence from work on human tissue also indicated
that the cell-of-origin of TNBCs, basal-like carcinomas and
BRCA−/− tumors are luminal cells, in agreement with the
above results [76, 77]. More direct experimental evidence that
the cellular origin of human breast cancer is mostly luminal
comes from a study by Keller et al., in which normal mam-
mary epithelial cells from human tissue were sorted and trans-
formed using overexpression of oncogene combinations. Up-
on xenotransplantation in immunodeficient mice, transformed
CD10+ myoepithelial cells generated squamous, metaplastic
tumors, a subtype rarely seen in human patients, whereas
transformed luminal EpCAM+ cells generated tumors with
characteristics of both luminal and basal ductal carcinomas
[78]. Similar conclusions were reached by Kim et al., using
a different experimental approach [79].
These studies underscore that these are not semantic dis-
tinctions, because they determine which normal cells are to be
studied to understand the initiation and progression of breast
cancer. The name basal-like has been interpreted by some as
these tumors initiating in the myoepithelial layer. As a conse-
quence, researchers have targeted the basal cells to create
TNBC models in mice and cell culture models, not so seman-
tic considering the time and effort that has been invested in
these experiments.
Are the Cells that Co-express K5/14/17 and K7/8/18
Normal Breast Epithelial Progenitors?
The mistaken assumption that keratins K5/14/17 are never
expressed in the luminal layer had consequences for normal
stem cell research as well. This has led to the notion that the
cells that co-express luminal keratins K7/18/19 with K5/14/17
could be breast stem cells [30, 80], because co-expression of
different lineage restricted markers in the same cell has indeed
been a feature of genuine stem cells in other tissues.
There is evidence suggesting that K5/K18 or K14/K18
double positive cells may be enriched for progenitors com-
pared to other breast cell populations. However, we found that
25 % of K18(+) luminal cells are also K5 (+) (n=879) and
36% are K14 (+) (n=354) on average [23, 33, 81]. In addition
to these averages, some lobules are found to be entirely com-
posed of K5/K18 double-positive luminal cells (Fig. 6) [23,
33, 58]. Such lobules have been found in all the sections that
we have examined with multiplex staining. Since adult tissues
cannot be composed of stem cells entirely, it is unlikely that all
K5/K18(+) or K14/K18 (+) double positive cells are stem
cells [82].
In contrast with these observations in the human breast, the
K5 (+) or K14 (+) luminal cells are not found in the adult
mouse mammary gland, which is a significant difference in
the luminal cell phenotypes between these species [83]. Rare
K14 (+) luminal cells are found at birth and during puberty in
mice, whereas K5(+) luminal cells were not found at any
developmental stage of the mouse mammary gland [83]. It
appears that K5/14 are exclusively expressed in the
myoepithelial layer of adult mouse breast [83]. Intriguingly,
rare K6 (+) luminal mammary cells were found in adult mice
[84]. Given the relative abundance of luminal K5/14 (+) cells
in the adult human breast, this major difference in the spec-
trum of luminal cell differentiation raises further questions
about extrapolation of results from mouse models to humans.
Classification of Breast Cancers Based on Normal
Lineages
The correct benchmark to determine cellular phenotype of
human breast cancers must begin with the description of nor-
mal cell types in the lobules, where practically all human
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breast cancers initiate with the exception of papillomas [42,
44, 45]. As described above, the normal luminal breast cell
types conform to four hormonal states based on the co-
expression of ER, AR and VDR [23, 33]. The triple hormone
receptor positive HR3 cells co-express ER, AR and VDR
simultaneously, HR0 cells express none of the three, HR2
express ER/AR, ER/VDR or AR/VDR and the HR1 cells
express a single receptor (Fig. 7) [23, 33].
When human tumors were examined for these lineages, we
found that nearly all of the human tumors are similar to one of
the normal cell types [23, 33]. In fact, each patient tumor was
similar to one of the 10 normal cell types. This result is rem-
iniscent of lymphomas and leukemias that resemble distinct
steps in the differentiation hierarchy of normal hematopoiesis,
where there is a malignant counterpart for each stage of dif-
ferentiation [85–87].
Importantly, in multivariate analysis we found that that HR3
tumors have the best survival, HR1/0 tumors have the worst
survival, and HR2 tumors have intermediate survival, with a
relative hazard ratio of 6.9 fold between HR3 vs. HR0 tumors
(p <0.0001) [23, 33], which is much higher than many of the
traditional and molecular prognostic signatures. Hence, the nor-
mal cell type based classification revealed groups of breast
cancer that have very significant clinical outcome differences.
The examination of the three standard breast cancer sub-
types from the perspective of normal HR lineages also re-
vealed some interesting insights. It was found that ~75 % of
ER+ tumors have a triple positive HR3 phenotype. The re-
mainder of ER+ tumors resemble normal HR2 ER/AR+, ER/
VDR+, or HR1 ER+ cells. The TNBC tumors resemble six
normal lineages including HR2 AR/VDR(+), HR1 AR(+),
HR1 VDR(+), HR1 K5/VDR(+), HR0 K5(+) and HR0
K5(−) (Fig. 7) [23, 33].
Interestingly, HER2+ tumors seem to arise from all luminal
lineages except those that express K5 (Fig. 7). It is intriguing
to speculate whether amplification of HER2 is somehow not
permissible in K5(+) luminal cells. A similar observation was
made for the retinoblastoma (Rb) gene; it was found that de-
letion of Rb affected four of the seven cell types in the retina,
but not amacrine, horizontal or glial cells [88–90]. It was later
shown that Rb depletion results in formation of retinoblasto-
mas only in cone cells but not in other retinal cells [91].
Everything Should be as Simple as Possible, but no More
In popular culture, physicists are sometimes portrayed as fond
of simpler equations that explain a phenomenon, simplicity of
an answer often being thought to signify a deeper understand-
ing. Nevertheless, as the father of one of the simplest and most
powerful equations in science, Einstein said; ‘everything
should be as simple as possible, but not more simple’, warning
us against over-simplification.
Dichotomies such as ‘ductal vs. luminal’ or ‘basal vs. lu-
minal’ are very seductive in their simplicity. And they have
served a useful purpose to advance research in this field. How-
ever, it is increasingly becoming clear that individual tumors
can have both ductal and luminal components, co-existing
simultaneously [92–94]. Furthermore, the evidence reviewed
here indicates that human breast has tremendous heterogene-
ity with manymore cell types than just basal and luminal cells.
Therefore, these simplistic dichotomies may have exhausted
their useful life and it may be time to move beyond them.
Comparative Tissue Biology of Breast Stem Cells
Lastly, the observations above highlight the need for involve-
ment of comparative tissue biologists as referees in stem cell
research. Over the past century several distinct disciplines of
biology have emerged, such as molecular biology, cell biolo-
gy, evolutionary biology, to address distinct questions utiliz-
ing specific expertise and methodology. Eventually these
fields were organized into distinct academic departments or
graduate programs.
It is not an overstatement to suggest that examining mole-
cules and cells in the context of a tissue is as challenging as
any other field of biology. Yet, there are no graduate programs
or departments of Btissue biology .^
A group of research pathologists have recently pointed out
the need for more formal comparative tissue biology training,
in a letter entitled Do-it-yourself (DIY) pathology in Nature
Biotechnology [1]:
Those of us with comparative pathology expertise have
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Fig. 7 The K18 (+) luminal cell types found in normal human breast
lobules and their malignant counterparts
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studies have been published over the past decade with-
out a pathologist among the authors, collaborators or
consultants. Furthermore, based on the frequently inac-
curate use of pathology terms and misinterpretation of
data in many of these studies, it appears that not only the
authors but also the reviewers and editors often have
neglected to consult a comparative pathologist during
the evaluation of such manuscripts [1].
As we have reviewed here, it is difficult to ignore DIY
pathology as one of the sources of ongoing controversies in
breast stem cell research. Let us not forget that it was pathol-
ogists who first put forward the concepts that constitute the
current cancer stem cell model, including the hypothesis that
tumorigenesis is aberrant organogenesis [95].
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